Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spotlight On TissueGene’s Upcoming Korea IPO

Executive Summary

Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.

Advertisement

Related Content

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
AbClon Shines On Korean Debut Amid Robust Investor Interest
Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel